FDA approves Pfizer’s Vyndaqel, Vyndamax for cardiomyopathy in rare protein disorder
An analyst wrote that the drug's high price tag of $225,000 could limit its uptake in ATTR-CM, but it could become competitive with Alnylam's Onpattro.
FDA approves Alnylam’s siRNA drug Onpattro for rare disorder
The drug is the first approved treatment for the condition, as well as the first siRNA drug to win the agency's approval.
The Hidden Administrative Tasks Draining Small Practices
Small practices play a critical role in healthcare delivery, but they cannot continue to absorb ever-increasing administrative demands without consequences.